Quick Connect Send a message
Health Canada’s market authorisation for our generic Semaglutide Injection makes us the first company to receive this authorisation in Canada. This milestone reflects our deep focus on complex generics and peptide‑based therapies, underpinned by integrated API and formulation development capabilities.
With launch preparations underway, we are working to enable timely access to an important treatment option for people living with diabetes in Canada.
+91 4049002253